Open-capsule budesonide for the treatment of immune-related enteritis from checkpoint inhibitors.

Patrick Tiongco MagahisTara CorsoPamela LivingstoneErika TomAmitabh SrivastavaMichael A Postow David M Faleck

Published in: Journal for immunotherapy of cancer (2024)

OCB is a safe and effective therapy for irEnteritis. OCB avoids systemic immunosuppression and successfully achieves clinical response and remission even in patients previously nonresponsive to systemic corticosteroids. Future studies are needed to optimize indications and duration.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
dna damage
prognostic factors
minimally invasive
peritoneal dialysis
cell cycle
current status
rheumatoid arthritis
combination therapy
case control